Venue
Lake Biel Switzerland 8th-11th of September
Program
- European Innovation Partnership on Active and Healthy
Ageing.
- Involvement and identification of specific aims towards
- Patients Role, Stem Cell and Drug Safety and Epigenetic
Profiling
Specific Topics
- What are the Patients orientated needs with focus on
quality of live and satisfaction?
- How could the role of pharma industry be changed from
drug producer and target for juristic trails to a respected patients partner?
- What significant measures are important to improve the
communication between patients, health policy and pharma industry and regulators beyond
marketing level?
- How could patients be better informed with
implementation of IT-Technology?
- What are the measures to track down changes in
patient’s satisfaction?
- How to generate efficiently the paradigm change from
weighting clinical indicators such as surrogate response and endpoints for quality of
life towards individualized medicine and regenerative medicine with bench to bed
approaches in integrated scenarios?
- What is the potential of stem cell technology
concerning drug safety?
- What it’s the state of art status of cell based
therapies usage in clinical practice?
- Offers regenerative medicine the solution for “Long
Live Living” in dignity?
Dr. Mary Baker
- “The sad thing is that pharma companies are not
involved in the major health systems; they’re peripheral. They should not be seen as a
cost, they should be seen as a trusted partner.“
- Current Member of the Strategic Advisory Board of the
Human Brain Project Immediate Past President of the European Brain Council
- Past President of the European Federation of
Neurological Associations
- Associate Membership of the Health Services Research
Unit, University of Oxford
- Visiting Fellow within the London School of Economics
(LSE) Health Centre Consultant to the World Health Organisation (WHO)
Dr. Mary Baker, MBE
Management Board of the European Medicines Agency (EMEA) Chair of the Working Group on
Parkinson’s Disease
Thomas Bols
Vice President, Corporate Affairs EU, Biogen International GmbH, CH
Marco Cappato
Segretario dell “Associazione Luca Coscioni“ per la libertà di ricerca scientifica, Italia,
Member of the City Council Milan, Italy
Prof. Tomas J Ekstrom
Dept. of Clinical Neuroscience, Karolinska Institutet, Sweden
Prof. Miomir Knezevic
National Institute of Biology University of Ljubljana, Slovenia
Dr. Stephen Minger
Senior Consultant in Cellular Sciences and Regenerative for GE Healthcare Life Sciences,
Director of SLM Blue Skies Innovations Ltd,UK
Dr. Jeya Prakash
Age Management Consultant, Harley Street, London, UK
Dr. Thomas Syburra
Senior Consultant Cardiac Surgeon, Dept. Lucerne Kantonhospital,Switzerland.
Major, Swiss
Air Force, Swiss Armed Forces
Prof. Ralph Tonjes
Paul-Ehrlich-Institute Federal Institute for Vaccines and Bio medicines,
Division of Medical Biotechnology, Head of Section,Non-vital Tissue Preparations,
Xenogeneic Cell Therapeutics, Germany; Goethe University, Frankfurt/Main, Germany
Project Coordinator / CEO: Dr. Marco Traub
Trans European Stem Cell Therapy Society, Bern; London
